Tulane in the News

Health, People, Science
HealthExec: The healthiest and unhealthiest US cities
NOLA, People
WWLTV: Maybell Romero, Tulane University Professor of Law recaps Frickey trial
Health, People, Science
The Atlantic: Ozempic Is About to Be Old News
Health, People, Science, World
Associated Press: Wall Street dips, snaps win streak after weak economic data
Health, People, Science
Times of News: Does getting a cold often increase your risk for dementia? New study finds link
Culture, NOLA
Voice of America: New Orleans Embraces Its French Roots
Culture
Bloomberg: Living the Dream? The Realities of Female Homeownership
Culture, Science
MSN.com: Will coastal regions still be safe for snowbirds in 25 years?
People
The New York Times: Trump’s Indictment and What’s Next
Health, People
Times Union: Mice and no heat: Behind the struggle to hold landlords accountable
Health, People, Science
Grist: Does Your Community Have Lead in Its Soil? Here's What To Do.
Health, People, Science
Study Finds: Fact Or Fiction: 10 Common Beliefs About Sun Damage & Skin Health
People, Science, World
The Washington Post: Companies bid $264M in Gulf oil sale mandated by climate law
Culture, People
The New York Times: Money Is Up. Patriotism and Religion Are Down.
Health, NOLA, On Campus, People, Science
New Orleans City Business: Tulane University School of Medicine debuts new robot-assisted transplant surgery
Health, People, Science
Healthline: Social Anxiety: Odors from Other People’s Sweat May Help Ease Symptoms
Health, NOLA, People, Science
La Illuminator: Postpartum Medicaid expansion is the first step to maternal health equity, experts say
On Campus, People
WWNO: A conversation with Walter Isaacson, professor and biographer awarded National Humanities Medal
Health, People, Research in Real Time, Science
Center for Public Integrity: Lead Keeps Poisoning Children. It Doesn’t Have to.
Health, People, Science
Targeted Oncology: Pedro C. Barata, MD, MSc, assistant professor of medicine at Tulane University School of Medicine, discusses the efficacy and tolerability of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for patients with clear cell renal cell car